Skin toxicity is a frequent adverse event of EGFR targeting agents. The role of cetuximab induced skin toxicity (Cet-ST), for the most acneiform skin rash, as a prognostic or a predictive factor of treatment efficacy is currently under discussion.
Conclusions
-Cetuximab-related skin toxicity (mostly acneiform rash) is a strong predictor of outcome.
-First-cycle rash predicts favourable outcome.
-Cet-ST appears to be rather a prognostic than a predictive factor since this effect is most evident in patients with KRAS codon-12 mutant tumors.
-EGFR intron-1 polymorphism appears to be a predictor of Cet-ST. 
